Reason for request
Inclusion on the list of medicines approved for hospital use in the extension of the indication to the treatment of atypical haemolytic uremic syndrome (aHUS).
Clinical Benefit
| Substantial |
The actual benefit of SOLIRIS 300 mg, concentrate for solution for infusion, is substantial in this indication. |
Clinical Added Value
| important |
SOLIRIS 300 mg, an orphan medicine, provides an important improvement in actual benefit (IAB II) compared to standard treatment for patients with aHUS. |
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
NL9Q6L1NKQmf58YT
